ArticleNature microbiology2025
Rational design of a hospital-specific phage cocktail to treat Enterobacter cloacae complex infections.
Article in Nature microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Receptor Structure Shapes Host Range but Incompletely Predicts High Activity inAntibiotics (Basel, Switzerland) · 2026Article
- Genome sequences of sixMicrobiology resource announcements · 2026Article
- A Lytic Bacteriophage Cocktail Attenuates Carbapenem-Resistant Klebsiella pneumoniae-Acinetobacter baumannii Mixed-Species Biofilms and Reshapes Transcriptional Responses.Microbial biotechnology · 2026Article
- WaaL-WaaP receptor cross-talk drives phage-induced collateral sensitivity to colistin in Salmonella Pullorum.Veterinary research · 2026Article
- Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges.Archives of microbiology · 2026Review
- Genome-Guided Discovery of Vaccine Targets for a Multi-Epitope Construct Against Multidrug-Resistant Enterobacter cloacae.MicrobiologyOpen · 2026Article
- Cross-reactive anti-prophage antibodies and bacterial heteroresistance implicated in phage therapeutic failure.Nature medicine · 2026Article
- Review
- Characterization of the bacteriophage vB_KpnP_Henu1_3 lytic for K1Microbiology spectrum · 2026Article
- Bacteriophage Therapy AgainstMicroorganisms · 2026Review
- The Role of Genomics in Advancing and Standardising Bacteriophage Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Next-generation anti-infective drugs in the post-antibiotic era: focusing on anti-virulence agents targeting the bacterial quorum sensing system.Frontiers in cellular and infection microbiology · 2026Review
- Genomic and functional characterization of novel therapeutic lytic bacteriophages targeting multidrug-resistantFrontiers in microbiology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
The Alfred Hospital in Melbourne, Australia, has reported an ongoing outbreak of infections caused by multidrug-resistant Enterobacter cloacae complex (ECC). Phage therapy is a promising strategy to treat antimicrobial-resistant infections. Utilizing the hospital's isolate collection, built over the past decade, we established an initial 3-phage cocktail with 54% ECC coverage. We then iteratively improved this product by enhancing phage killing efficiency using phage adaptation and expanded host range through targeted phage isolation against low-coverage ECC isolates. This optimization yielded Entelli-02, containing five well-characterized virulent phages that target clinical ECC isolates via distinct bacterial cell surface receptors. Entelli-02 exhibits 88% host coverage against The Alfred Hospital's ECC isolate collection (n = 206), confirmed by plaque formation and reduced bacterial load in septicaemic mice by >99%. We produced this cocktail as a therapeutic-grade product, ready for clinical use. Entelli-02 represents a hospital-specific phage cocktail with frontline efficacy and on-demand availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.